Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure

Onkologie. 2007 Feb;30(1-2):65. doi: 10.1159/000098704. Epub 2007 Jan 26.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Humans
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / drug therapy
  • Leucovorin / administration & dosage
  • Leucovorin / adverse effects
  • Male
  • Rectal Neoplasms / complications*
  • Rectal Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • IFL protocol